Santarus
San Diego
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Total funding: $89.4M
- Funding stage: M&A
- Last round: Series D (May 2003)
- Ticker: nasdaq:SNTS
- Website: santarus.com
- Phone: 8583145705
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/santarus-1827747 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.